Arcus Biosciences Operating Expenses Growth & History (RCUS)
Arcus Biosciences's operating expenses was $633.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $633.0M | $45.0M | +7.65% |
| 2024 | 2024-12-31 | $588.0M | $131.0M | +28.67% |
| 2023 | 2023-12-31 | $457.0M | $65.0M | +16.58% |
| 2022 | 2022-12-31 | $392.0M | $63.0M | +19.15% |
| 2021 | 2021-12-31 | $329.0M | $127.0M | +62.87% |
| 2020 | 2020-12-31 | $202.0M | $98.3M | +94.78% |
| 2019 | 2019-12-31 | $103.7M | $40.5M | +64.07% |
| 2018 | 2018-12-31 | $63.2M | $8.4M | +15.24% |
| 2017 | 2017-12-31 | $54.9M | $36.7M | +201.69% |
| 2016 | 2016-12-31 | $18.2M | — | — |
Arcus Biosciences quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $137.0M | −$31.0M | −18.45% |
| Q1 2026 | 2026-03-31 | $151.0M | $1.0M | +0.67% |
| Q4 2025 | 2025-12-31 | $147.0M | $18.0M | +13.95% |
| Q3 2025 | 2025-09-30 | $168.0M | $15.0M | +9.80% |
| Q2 2025 | 2025-06-30 | $168.0M | $23.0M | +15.86% |
| Q1 2025 | 2025-03-31 | $150.0M | −$11.0M | −6.83% |
| Q4 2024 | 2024-12-31 | $129.0M | $7.0M | +5.74% |
| Q3 2024 | 2024-09-30 | $153.0M | $41.0M | +36.61% |
| Q2 2024 | 2024-06-30 | $145.0M | $33.0M | +29.46% |
| Q1 2024 | 2024-03-31 | $161.0M | $50.0M | +45.05% |
| Q4 2023 | 2023-12-31 | $122.0M | $14.0M | +12.96% |
| Q3 2023 | 2023-09-30 | $112.0M | $9.0M | +8.74% |
| Q2 2023 | 2023-06-30 | $112.0M | $16.0M | +16.67% |
| Q1 2023 | 2023-03-31 | $111.0M | $26.0M | +30.59% |
| Q4 2022 | 2022-12-31 | $108.0M | $34.4M | +46.74% |
| Q3 2022 | 2022-09-30 | $103.0M | $15.4M | +17.58% |
| Q2 2022 | 2022-06-30 | $96.0M | $10.4M | +12.15% |
| Q1 2022 | 2022-03-31 | $85.0M | $2.8M | +3.40% |
| Q4 2021 | 2021-12-31 | $73.6M | $12.1M | +19.67% |
| Q3 2021 | 2021-09-30 | $87.6M | $24.6M | +39.09% |
| Q2 2021 | 2021-06-30 | $85.6M | $38.5M | +81.64% |
| Q1 2021 | 2021-03-31 | $82.2M | $52.1M | +172.66% |
| Q4 2020 | 2020-12-31 | $61.5M | $34.2M | +125.46% |
| Q3 2020 | 2020-09-30 | $63.0M | $38.0M | +151.92% |
| Q2 2020 | 2020-06-30 | $47.1M | $16.2M | +52.46% |
| Q1 2020 | 2020-03-31 | $30.1M | $9.6M | +46.91% |
| Q4 2019 | 2019-12-31 | $27.3M | $12.2M | +81.29% |
| Q3 2019 | 2019-09-30 | $25.0M | $8.6M | +52.10% |
| Q2 2019 | 2019-06-30 | $30.9M | $13.8M | +80.24% |
| Q1 2019 | 2019-03-31 | $20.5M | $5.9M | +40.75% |
| Q4 2018 | 2018-12-31 | $15.0M | $452,000 | +3.10% |
| Q3 2018 | 2018-09-30 | $16.4M | −$6.9M | −29.45% |
| Q2 2018 | 2018-06-30 | $17.1M | $7.5M | +77.45% |
| Q1 2018 | 2018-03-31 | $14.6M | $7.3M | +99.74% |
| Q4 2017 | 2017-12-31 | $14.6M | — | — |
| Q3 2017 | 2017-09-30 | $23.3M | — | — |
| Q2 2017 | 2017-06-30 | $9.7M | — | — |
| Q1 2017 | 2017-03-31 | $7.3M | — | — |
Arcus Biosciences operating expenses trends
Over the last five fiscal years, Arcus Biosciences's operating expenses increased from $202.0M to $633.0M, a change of $431.0M. The latest reported quarter, Q2 2026, shows $137.0M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗